Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Use of Pregabalin and Worsening Heart Failure: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of Proton Pump Inhibitors and the Risk of Acute Kidney Injury Among Patients with Rheumatoid Arthritis: Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Psychiatric morbidity among men using anabolic steroids

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Experiences from the adverse drug event manager

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Healthcare resource utilization in patients with treatment-resistant depression—A Danish national registry study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Short-term mortality following tramadol poisonings in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: In Denmark, physicians are legally obliged to report serious adverse drug reactions (ADRs), such as intracranial hemorrhage (ICH) following anticoagulant (AC) treatment, to the Danish Medicines Agency. We were therefore puzzled to discover a high number of reports concerning ICHs following treatment with the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin. This was surprising, as all DOACs have been found to be associated with a lower risk of ICH compared with warfarin in phase III randomized controlled trials.

OBJECTIVES: The primary aim of the study was to estimate the level of underreporting of ICH as an ADR following treatment with warfarin, dabigatran, rivaroxaban, and apixaban.

METHODS: This observational study covered a 5-year period (2014-2018). Using nationwide registries held by the Danish Health Data Authority, the number of users, exposure time in person-years, and related ICH events for each of the study drugs were estimated. Data on ADR-ICH reports were extracted from the interactive ADR overviews held by the Danish Medicines Agency.

RESULTS: From 2014 to 2018, 97.0% of the identified warfarin-related ICH events were not reported as ADRs. For the DOACs, the level of underreporting ranged from 88.8 to 90.8%.

CONCLUSION: We found a heavy and differentiated level of underreporting of ICH as an ADR following treatment with the four study drugs.

OriginalsprogEngelsk
TidsskriftDrug Safety
Vol/bind45
Udgave nummer4
Sider (fra-til)379-388
Antal sider10
ISSN0114-5916
DOI
StatusUdgivet - apr. 2022

Bibliografisk note

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

ID: 85653986